Check Your Eligibility
Answer a few questions to see if you may qualify for this trial.
Step 1 of 8
Have you ever received treatment with an immune checkpoint inhibitor drug, such as pembrolizumab, nivolumab, atezolizumab, or ipilimumab?
This study is specifically designed for patients new to checkpoint inhibitor treatment. If you've had these drugs before, you would not qualify for this trial.
Show original medical criteria
This trial is for patients who have NOT previously received checkpoint inhibitor therapy (checkpoint inhibitor naïve). Prior anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 therapy makes you ineligible.
This is informational only — not medical advice. Always discuss eligibility with your oncologist.